Loading...
Loading...
- Adaptimmune Therapeutics plc ADAP is merging with TCR² Therapeutics Inc TCRR in an all-stock deal to create a cell therapy company focused on treating solid tumors.
- The lead clinical franchises for the combined company utilize engineered T-cell therapies targeting MAGE-A4 and mesothelin.
- These targets are expressed on a broad range of solid tumors.
- Related: TCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesothelioma.
- The combined company also has a preclinical pipeline of additional target opportunities, with development initially focused on PRAME and CD70.
- With a cash runway extended into early 2026, the new company will keep the Adaptimmune name and be run by the same team led by Adaptimmune CEO Adrian Rawcliffe.
- Also Read: GSK Transfers Cell Therapy Program Rights To Adaptimmune, Terminates Second Cell Therapy Pact In A Day
- Shareholders of Adaptimmune will emerge as the majority owner of the new company, owning around 75% of the shares.
- The transaction is currently expected to close in Q2 2023.
- As of December 31, 2022, Adaptimmune had cash and cash equivalents of $108.0 million.
- The company reported Q4 sales of $11.03 million, beating the consensus of $4.12 million.
- Q4 EPS came in at $(0.18) better than the analyst estimate of $(0.25).
- Price Action: ADAP shares are down 20.70% at $1.40, and TCRR shares are up 33.80% at $1.62 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in